Trajectories of Serum Hepatitis B Surface antigen (HBsAg) During Treatment and Association With HBsAg Loss in Children With Hepatitis B e Antigen-Positive Chronic Hepatitis B: A Latent Class Trajectory Analysis

被引:0
作者
Yao, Zhenzhen [1 ]
Gu, Yingping [1 ]
Lai, Xin [1 ]
Yang, Meng [1 ]
Xu, Yi [1 ]
Luo, Jiayou [1 ]
Peng, Songxu [1 ,2 ]
机构
[1] Cent South Univ, Xiangya Sch Publ Hlth, Dept Maternal & Child Hlth, 172 Tongzipo Rd, Changsha 410078, Peoples R China
[2] Hunan Prov Maternal & Child Hlth Care Hosp, NHC Key Lab Birth Defect Res & Prevent, Changsha, Hunan, Peoples R China
基金
中国国家自然科学基金;
关键词
serum HBsAg; trajectory; HBsAg loss; HBeAg-positive CHB; children; HEPATOCELLULAR-CARCINOMA; VIRUS DNA; HBEAG; SEROCLEARANCE; ALPHA-2A; THERAPY;
D O I
10.1093/infdis/jiae349
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Changes in serum hepatitis B surface antigen (HBsAg) during treatment are associated with HBsAg loss. However, little is known about the trajectory patterns of HBsAg in early treatment and their relationship to subsequent HBsAg loss.Methods A retrospective study was conducted on 166 treatment-naive children with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB). Latent class trajectory analysis was used to identify trajectory groups of serum HBsAg. Cox proportional hazards models were used to assess the association between HBsAg trajectory groups and HBsAg loss.Results The median follow-up time was 20.70 (interquartile range, 12.54-34.17) months, and HBsAg loss occurred in 70 (42.17%) of all study participants. Using latent class trajectory analysis, HBeAg-positive patients with CHB were classified into 3 trajectory groups: trajectory 1 (sustained stability, 24.70%), trajectory 2 (slow decline, 38.55%), and trajectory 3 (rapid decline, 36.75%), respectively. The risk of achieving HBsAg loss was higher in both trajectory 2 (hazard ratio, 3.65 [95% confidence interval, 1.70-7.83]) and trajectory 3 (7.27 [3.01-17.61]), respectively.Conclusions Serum HBsAg levels during early treatment can be classified into distinct trajectory groups, which may serve as an additional predictive indicator for HBsAg loss in HBeAg-positive children with CHB. HBsAg levels in pediatric patients with HBeAg-positive chronic hepatitis B during early treatment can be divided into 3 trajectory groups (sustained stability, slow decline, and rapid decline); the risk of HBsAg loss varies greatly between trajectories. Graphical Abstract
引用
收藏
页码:196 / 203
页数:8
相关论文
共 33 条
[1]   Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial [J].
Bourliere, Marc ;
Rabiega, Pascaline ;
Ganne-Carrie, Nathalie ;
Serfaty, Lawrence ;
Marcellin, Patrick ;
Barthe, Yoann ;
Thabut, Dominique ;
Guyader, Dominique ;
Hezode, Christophe ;
Picon, Magali ;
Causse, Xavier ;
Leroy, Vincent ;
Bronowicki, Jean Pierre ;
Carrieri, Patrizia ;
Riachi, Ghassan ;
Rosa, Isabelle ;
Attali, Pierre ;
Molina, Jean Michel ;
Bacq, Yannick ;
Tran, Albert ;
Grange, Jean Didier ;
Zoulim, Fabien ;
Fontaine, Helene ;
Alric, Laurent ;
Bertucci, Inga ;
Bouvier-Alias, Magali ;
Carrat, Fabrice .
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (03) :177-188
[2]   Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon α-2b [J].
Buster, Erik H. C. J. ;
Flink, Hajo J. ;
Cakaloglu, Yilmaz ;
Simon, Krzysztof ;
Trojan, Joerg ;
Tabak, Fehmi ;
So, Thomas M. K. ;
Feinman, S. Victor ;
Mach, Tomasz ;
Akarca, Ulus S. ;
Schutten, Martin ;
Tielemans, Wanda ;
van Vuuren, Anneke J. ;
Hansen, Bettina E. ;
Janssen, Harry L. A. .
GASTROENTEROLOGY, 2008, 135 (02) :459-467
[3]   PREDICTORS OF CLINICAL RESPONSE: RESULTS FROM A LARGE, RANDOMIZED CONTROLLED STUDY WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) PLUS PEGINTERFERON ALFA-2A (PEG) COMBINATION FOR CHRONIC HEPATITIS B (CHB) [J].
Chan, H. L. ;
Ahn, S. H. ;
Chuang, W. L. ;
Hui, A. J. ;
Tabak, F. ;
Mehta, R. ;
Petersen, J. ;
Lee, C. -M. ;
Ma, X. ;
Caruntu, F. A. ;
Tak, W. Y. ;
Elkhashab, M. ;
Lin, L. ;
Dinh, P. ;
Martins, E. B. ;
Charuworn, P. ;
McHutchinson, J. G. ;
Subramanian, G. M. ;
Lim, S. G. ;
Foster, G. R. ;
Fung, S. ;
Morano, L. ;
Samuel, D. ;
Agarwal, K. ;
Idilman, R. ;
Strasser, S. ;
Buti, M. ;
Gaeta, G. B. ;
Papatheodoridis, G. ;
Flisiak, R. ;
Marcellin, P. .
JOURNAL OF HEPATOLOGY, 2015, 62 :S251-S252
[4]   Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children [J].
Chang, MH ;
Chen, CJ ;
Lai, MS ;
Hsu, HM ;
Wu, TC ;
Kong, MS ;
Liang, DC ;
Shau, WY ;
Chen, DS .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (26) :1855-1859
[5]   The role of quantitative hepatitis B surface antigen revisited [J].
Cornberg, Markus ;
Wong, Vincent Wai-Sun ;
Locarnini, Stephen ;
Brunetto, Maurizia ;
Janssen, Harry L. A. ;
Chan, Henry Lik-Yuen .
JOURNAL OF HEPATOLOGY, 2017, 66 (02) :398-411
[6]   HBsAg seroclearance with NUCs: rare but important [J].
Cornberg, Markus ;
Siederdissen, Christoph Hoener Zu .
GUT, 2014, 63 (08) :1208-U39
[7]   Mean HBsAg decline at week 24 of PEG-IFN-based treatment predicts subsequent rate of HBsAg clearance - suggesting a valuable endpoint for early development HBV trials [J].
De Ridder, Filip ;
Sonneveld, Milan J. ;
Lenz, Oliver ;
Janssen, Harry L. A. ;
Talloen, Willem ;
Hansen, Bettina E. .
JOURNAL OF VIRAL HEPATITIS, 2021, 28 (11) :1563-1569
[8]   Chronic hepatitis B in children: Therapeutic challenges and perspectives [J].
Defresne, Florence ;
Sokal, Etienne .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 (02) :368-371
[9]   Trajectories of body mass index before the diagnosis of cardiovascular disease: a latent class trajectory analysis [J].
Dhana, Klodian ;
van Rosmalen, Joost ;
Vistisen, Dorte ;
Ikram, M. Arfan ;
Hofman, Albert ;
Franco, Oscar H. ;
Kavousi, Maryam .
EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2016, 31 (06) :583-592
[10]   Hepatitis B Surface Antigen Loss: Too Little, Too Late and the Challenge for the Future [J].
Dusheiko, Geoffrey ;
Wang, Bo .
GASTROENTEROLOGY, 2019, 156 (03) :548-551